Targeted anti-IL-1? platelet microparticles for cardiac detoxing and repair.

ABSTRACT: An acute myocardial infarction (AMI) induces a sterile inflammatory response that facilitates further heart injury and promotes adverse cardiac remodeling. Interleukin-1? (IL-1?) plays a central role in the sterile inflammatory response that results from AMI. Thus, IL-1? blockage is a promising strategy for treatment of AMI. However, conventional IL-1? blockers lack targeting specificity. This increases the risk of serious side effects. To address this problem herein, we fabricated platelet microparticles (PMs) armed with anti-IL-1? antibodies to neutralize IL-1? after AMI and to prevent adverse cardiac remodeling. Our results indicate that the infarct-targeting PMs could bind to the injured heart, increasing the number of anti-IL-1? antibodies therein. The anti-IL-1? platelet PMs (IL1-PMs) protect the cardiomyocytes from apoptosis by neutralizing IL-1? and decreasing IL-1?-driven caspase-3 activity. Our findings indicate that IL1-PM is a promising cardiac detoxification agent that removes cytotoxic IL-1? during AMI and induces therapeutic cardiac repair.

SUBMITTER: Li Z 

PROVIDER: S-EPMC7002120 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature